These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 25766325)
1. A benzimidazole derivative exhibiting antitumor activity blocks EGFR and HER2 activity and upregulates DR5 in breast cancer cells. Chu B; Liu F; Li L; Ding C; Chen K; Sun Q; Shen Z; Tan Y; Tan C; Jiang Y Cell Death Dis; 2015 Mar; 6(3):e1686. PubMed ID: 25766325 [TBL] [Abstract][Full Text] [Related]
2. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib. Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780 [TBL] [Abstract][Full Text] [Related]
3. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells. Asanuma H; Torigoe T; Kamiguchi K; Hirohashi Y; Ohmura T; Hirata K; Sato M; Sato N Cancer Res; 2005 Dec; 65(23):11018-25. PubMed ID: 16322251 [TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413 [TBL] [Abstract][Full Text] [Related]
5. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft. Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847 [TBL] [Abstract][Full Text] [Related]
6. Platycodin D inhibits migration, invasion, and growth of MDA-MB-231 human breast cancer cells via suppression of EGFR-mediated Akt and MAPK pathways. Chun J; Kim YS Chem Biol Interact; 2013 Oct; 205(3):212-21. PubMed ID: 23867902 [TBL] [Abstract][Full Text] [Related]
7. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification. Tanizaki J; Okamoto I; Fumita S; Okamoto W; Nishio K; Nakagawa K Oncogene; 2011 Sep; 30(39):4097-106. PubMed ID: 21499301 [TBL] [Abstract][Full Text] [Related]
8. Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells. Le XF; Arachchige-Don AS; Mao W; Horne MC; Bast RC Mol Cancer Ther; 2007 Nov; 6(11):2843-57. PubMed ID: 18025271 [TBL] [Abstract][Full Text] [Related]
9. The potential utility of acetyltanshinone IIA in the treatment of HER2-overexpressed breast cancer: Induction of cancer cell death by targeting apoptotic and metabolic signaling pathways. Guerram M; Jiang ZZ; Yousef BA; Hamdi AM; Hassan HM; Yuan ZQ; Luo HW; Zhu X; Zhang LY Oncotarget; 2015 Sep; 6(26):21865-77. PubMed ID: 26068969 [TBL] [Abstract][Full Text] [Related]
10. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim. Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280 [TBL] [Abstract][Full Text] [Related]
11. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Wainberg ZA; Anghel A; Desai AJ; Ayala R; Luo T; Safran B; Fejzo MS; Hecht JR; Slamon DJ; Finn RS Clin Cancer Res; 2010 Mar; 16(5):1509-19. PubMed ID: 20179222 [TBL] [Abstract][Full Text] [Related]
12. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib. Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051 [TBL] [Abstract][Full Text] [Related]
13. Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells. Ferreira RB; Wang M; Law ME; Davis BJ; Bartley AN; Higgins PJ; Kilberg MS; Santostefano KE; Terada N; Heldermon CD; Castellano RK; Law BK Oncotarget; 2017 Apr; 8(17):28971-28989. PubMed ID: 28423644 [TBL] [Abstract][Full Text] [Related]
14. Capsaicin causes cell-cycle arrest and apoptosis in ER-positive and -negative breast cancer cells by modulating the EGFR/HER-2 pathway. Thoennissen NH; O'Kelly J; Lu D; Iwanski GB; La DT; Abbassi S; Leiter A; Karlan B; Mehta R; Koeffler HP Oncogene; 2010 Jan; 29(2):285-96. PubMed ID: 19855437 [TBL] [Abstract][Full Text] [Related]
15. Chemotherapeutic Potential of 2-[Piperidinoethoxyphenyl]-3-Phenyl-2H-Benzo(b)pyran in Estrogen Receptor- Negative Breast Cancer Cells: Action via Prevention of EGFR Activation and Combined Inhibition of PI-3-K/Akt/FOXO and MEK/Erk/AP-1 Pathways. Saxena R; Chandra V; Manohar M; Hajela K; Debnath U; Prabhakar YS; Saini KS; Konwar R; Kumar S; Megu K; Roy BG; Dwivedi A PLoS One; 2013; 8(6):e66246. PubMed ID: 23840429 [TBL] [Abstract][Full Text] [Related]
16. Α-eleostearic acid inhibits growth and induces apoptosis in breast cancer cells via HER2/HER3 signaling. Zhuo RJ; Wang F; Zhang XH; Zhang JJ; Xu J; Dong W; Zou ZQ Mol Med Rep; 2014 Mar; 9(3):993-8. PubMed ID: 24425042 [TBL] [Abstract][Full Text] [Related]
17. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer. Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749 [TBL] [Abstract][Full Text] [Related]
18. Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models. Crafter C; Vincent JP; Tang E; Dudley P; James NH; Klinowska T; Davies BR Int J Oncol; 2015 Aug; 47(2):446-54. PubMed ID: 26095475 [TBL] [Abstract][Full Text] [Related]
19. Houttuyninum, an active constituent of Chinese herbal medicine, inhibits phosphorylation of HER2/neu receptor tyrosine kinase and the tumor growth of HER2/neu-overexpressing cancer cells. Zhou NN; Tang J; Chen WD; Feng GK; Xie BF; Liu ZC; Yang D; Zhu XF Life Sci; 2012 May; 90(19-20):770-5. PubMed ID: 22525372 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells. Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]